Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Dewpoint Therapeutics
Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development
November 17, 2026
From
Dewpoint Therapeutics
Via
GlobeNewswire
Dewpoint Therapeutics Reports Preclinical Data on Oral MYC Condensate Modulator at AACR 2026
April 21, 2026
From
Dewpoint Therapeutics
Via
GlobeNewswire
Dewpoint Therapeutics Selects First-in-Class MYC Condensate Modulator Development Candidate
February 11, 2026
From
Dewpoint Therapeutics
Via
GlobeNewswire
Dewpoint Therapeutics Doses First Patient in Phase 1a/2a Trial DPTX3186 for the Treatment of Advanced Solid Tumors, Focused on Gastric Cancer
February 04, 2026
From
Dewpoint Therapeutics
Via
GlobeNewswire
Dewpoint Therapeutics Announces TDP-43 Condensate Modulator Development Candidate for Treatment of ALS and Related Neurodegenerative Diseases
January 08, 2026
From
Dewpoint Therapeutics
Via
GlobeNewswire
Dewpoint Therapeutics Launches Initiative to Build Viral Condensate Phenomics Atlas for HPV
January 06, 2026
From
Dewpoint Therapeutics
Via
GlobeNewswire
FDA Grants Fast Track Designation to Dewpoint Therapeutics’ DPTX3186 for the Treatment of Gastric Cancer
November 17, 2025
From
Dewpoint Therapeutics
Via
GlobeNewswire
FDA Grants Orphan Drug Designation to Dewpoint Therapeutics’ DPTX3186 for the Treatment of Gastric Cancer
October 29, 2025
From
Dewpoint Therapeutics
Via
GlobeNewswire
Dewpoint Therapeutics Announces an Open IND for First-in-Class Condensate Modulator DPTX3186 for Wnt-Driven Cancers
October 21, 2025
From
Dewpoint Therapeutics
Via
GlobeNewswire
Dewpoint Therapeutics Announces Presentation at AACR-NCI-EORTC 2025
October 14, 2025
From
Dewpoint Therapeutics
Via
GlobeNewswire
Dewpoint Therapeutics Closes Series D Financing to Advance First-in-Class Condensate Modulator (c-mod) into Clinical Development for Gastric Cancer
September 10, 2025
From
Dewpoint Therapeutics
Via
GlobeNewswire
Dewpoint Therapeutics announces upcoming presentations at AACR 2025
March 26, 2025
From
Dewpoint Therapeutics
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.